Home/Filings/4/0001415889-24-029027
4//SEC Filing

Myles David C. 4

Accession 0001415889-24-029027

CIK 0001750284other

Filed

Dec 10, 7:00 PM ET

Accepted

Dec 11, 7:56 PM ET

Size

13.2 KB

Accession

0001415889-24-029027

Insider Transaction Report

Form 4
Period: 2024-12-09
Myles David C.
CH. DISCOV. & NON-CLIN DEV OFF
Transactions
  • Sale

    Common Stock

    2024-12-10$9.38/sh12,452$116,800611,947 total
  • Award

    Common Stock

    2024-12-09+48,750624,399 total
  • Sale

    Common Stock

    2024-12-11$9.39/sh300$2,817598,333 total
  • Sale

    Common Stock

    2024-12-11$8.66/sh13,314$115,299598,633 total
Holdings
  • Common Stock

    (indirect: See Footnote)
    12,831
  • Common Stock

    (indirect: See Footnote)
    154,846
Footnotes (8)
  • [F1]On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which were subject to vesting upon certification by the Compensation Committee of the Company's achievement of two different performance milestones. 35% of the award previously vested on November 20, 2023. On December 9, 2024, the Compensation Committee certified that the remaining 65% of the award vested based on achievement of certain performance criteria.
  • [F2]Includes 1,490 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.
  • [F3]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
  • [F4]The weighted average sale price for the transaction reported was $9.38, and the range of prices was between $8.89 and $9.67. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F5]The weighted average sale price for the transaction reported was $8.66, and the range of prices was between $8.22 and $9.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F6]The weighted average sale price for the transaction reported was $9.39, and the range of prices was between $9.31 and $9.74. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F7]The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
  • [F8]The shares are held by Myles Properties Inc., of which the Reporting Person is President.

Issuer

Olema Pharmaceuticals, Inc.

CIK 0001750284

Entity typeother

Related Parties

1
  • filerCIK 0001831216

Filing Metadata

Form type
4
Filed
Dec 10, 7:00 PM ET
Accepted
Dec 11, 7:56 PM ET
Size
13.2 KB